GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neurogene NGNE · USD

Health Care · US listing · 🇺🇸 United States

Compare

22.15

-3.40%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Neurogene — daily NGNE Delayed
Market value
$343.1m
Last close × shares
Volume
178.3k
Shares, 20 Nov 2026

About Neurogene

From its filings with the US Securities and Exchange Commission

SEC filings

Neurogene is based in New York, New York. Its shares trade on Nasdaq under the ticker NGNE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $90.4m. At that date it held total assets of $288.6m and shareholders' equity of $264.9m.

In its own words

Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming these limitations and turning today’s complex devastating neurological diseases into treatable conditions. We are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy. One approach we are taking harnesses our proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning), that utilizes microRNA-based genetic circuits designed to deliver therapeutic levels of transgene to key areas of the brain that underlie neurological disease pathology.

Our first clinical-stage program, NGN-401 in development for the treatment of Rett syndrome, utilizes the EXACT technology and adeno-associated virus (“AAV”) delivery. Rett syndrome is a severe and progressive neurodevelopmental disease with substantial neurological and physical impairment and significant unmet need. Our ongoing registrational trial of NGN-401, EmboldenTM, is a single-arm, open-label, baseline-controlled trial evaluating the 1E15 vg dose of NGN-401 in 20 females with Rett syndrome.

Quoted from its 10-K, filed 24 Mar 2026. Read the filing on SEC.gov ↗

More about Neurogene →

Latest on Neurogene

Our reporting

Next results

23 Nov 2026

Due on 23 Nov 2026. Analysts expect earnings of -1.39 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Neurogene's ticker?

Neurogene trades as NGNE on its US listing, under ISIN US64135M1053.

What was Neurogene's last closing price?

22.15 on 20 Nov 2026. The figure is in USD and is never converted.

When does Neurogene next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.